Patents by Inventor Barrett Allan

Barrett Allan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-IL-17 antibodies
    Patent number: 8110191
    Abstract: Anti-IL-17 antibodies are identified that are characterized as having a high affinity and slow off rate for human IL-17. The antibodies of the invention may be chimeric, humanized or fully human antibodies, immunoconjugates of the antibodies or antigen-binding fragments thereof. The antibodies of the invention are useful in particular for treating autoimmune, inflammatory, cell proliferative and developmental disorders.
    Type: Grant
    Filed: October 21, 2010
    Date of Patent: February 7, 2012
    Assignee: Eli Lilly and Company
    Inventors: Barrett Allan, Chi-Kin Chow, Ling Liu, Jirong Lu, Jonathan Wendell Tetreault, Ying Tang
  • CGRP ANTIBODIES
    Publication number: 20110305711
    Abstract: The present invention provides human engineered calcitonin gene related peptide (CGRP) antibodies or antigen-binding fragment thereof. In addition, the present invention provides the use of the human engineered calcitonin gene related peptide (CGRP) antibodies or antigen-binding fragment thereof for the treatment of osteoarthritis pain.
    Type: Application
    Filed: June 7, 2011
    Publication date: December 15, 2011
    Applicant: ELI LILLY AND COMPANY
    Inventors: Barrett ALLAN, Robert Jan BENSCHOP, Mark Geoffrey CHAMBERS, Ryan James DARLING
  • ANTI-IL-17 ANTIBODIES
    Publication number: 20110027290
    Abstract: Anti-IL-17 antibodies are identified that are characterized as having a high affinity and slow off rate for human IL-17. The antibodies of the invention may be chimeric, humanized or fully human antibodies, immunoconjugates of the antibodies or antigen-binding fragments thereof. The antibodies of the invention are useful in particular for treating autoimmune, inflammatory, cell proliferative and developmental disorders.
    Type: Application
    Filed: October 21, 2010
    Publication date: February 3, 2011
    Applicant: ELI LILLY AND COMPANY
    Inventors: Barrett Allan, Chi-Kin Chow, Ling Liu, Jirong Lu, Jonathan Wendell Tetreault
  • Anti-IL-17 antibodies
    Patent number: 7838638
    Abstract: Anti-IL-17 antibodies are identified that are characterized as having a high affinity and slow off rate for human IL-17. The antibodies of the invention may be chimeric, humanized or fully human antibodies, immunoconjugates of the antibodies or antigen-binding fragments thereof. The antibodies of the invention are useful in particular for treating autoimmune, inflammatory, cell proliferative and developmental disorders.
    Type: Grant
    Filed: December 5, 2006
    Date of Patent: November 23, 2010
    Assignee: Eli Lilly and Company
    Inventors: Barrett Allan, Chi-Kin Chow, Ling Liu, Jirong Lu, Jonathan Wendell Tetreault
  • Variant Fc regions
    Patent number: 7740847
    Abstract: The present invention provides humanized anti-CD20 antibodies comprising a human IgG1 Fc region comprising an isoleucine at position 247 and a glutamine at position 339 as well as nucleic acids encoding the antibodies and methods of using the antibodies for treating lymphoma. Furthermore, the invention provides compositions comprising the antibodies and methods of producing them.
    Type: Grant
    Filed: July 18, 2005
    Date of Patent: June 22, 2010
    Assignee: Applied Molecular Evolution, Inc.
    Inventors: Barrett Allan, Weidong Jiang, Ying Tang, Jeffry Dean Watkins
  • Anti-IL-17 Antibodies
    Publication number: 20080269467
    Abstract: Anti-IL-17 antibodies are identified that are characterized as having a high affinity and slow off rate for human IL-17. The antibodies of the invention may be chimeric, humanized or fully human antibodies, immunoconjugates of the antibodies or antigen-binding fragments thereof. The antibodies of the invention are useful in particular for treating autoimmune, inflammatory, cell proliferative and developmental disorders.
    Type: Application
    Filed: December 5, 2006
    Publication date: October 30, 2008
    Inventors: Barrett Allan, Chi-Kin Chow, Lihua Huang, Ling Liu, Jirong Lu, Kingman Ng, Jonathan Wendell Tetreault, Andrew Gordon Werner
  • Variant Fc Regions
    Publication number: 20070224188
    Abstract: The present invention provides polypeptides, particularly therapeutic antibodies, comprising a novel, variant Fc region. Furthermore the invention provides variant Fc regions which confer an altered effector function or altered serum half life upon a polypeptide to which it is operable attached.
    Type: Application
    Filed: July 18, 2005
    Publication date: September 27, 2007
    Inventors: Barrett Allan, Weidong Jiang, Ying Tang, Jeffry Watkins
  • Fc region variants
    Publication number: 20070141052
    Abstract: The present invention provides polypeptide Fc region variants and oligonucleotides encoding Fc region variants. Specifically, the present invention provides compositions comprising novel Fc region variants, methods for identifying useful Fc region variants, and methods for employing Fc region variants for treating disease.
    Type: Application
    Filed: February 20, 2004
    Publication date: June 21, 2007
    Inventors: Jeffry Watkins, Barrett Allan
  • Cd20 binding molecules
    Publication number: 20060251652
    Abstract: The present invention relates to CD20 binding molecules and nucleic acid sequences encoding CD20 binding molecules. In particular, the present invention relates to CD20 binding molecules with a high binding affinity, and a low dissociation rate, with regard to human CD20. Preferably, the CD20 binding molecules of the present invention comprise light and/or heavy chain variable regions with fully human frameworks (e.g. human germline frameworks).
    Type: Application
    Filed: May 20, 2004
    Publication date: November 9, 2006
    Inventors: Jeffry Watkins, Julian Davies, David Marquis, Barrett Allan, Brian Ondek
  • Fc region variants
    Publication number: 20060153838
    Abstract: The present invention provides polypeptide Fc region variants and oligonucleotides encoding Fc region variants. Specifically, the present invention provided compositions comprising novel Fc region variants, methods for identifying useful Fc region variants, and methods for employing Fc region variants for treating disease.
    Type: Application
    Filed: March 17, 2006
    Publication date: July 13, 2006
    Inventors: Jeffry Watkins, Barrett Allan
  • CD20 binding molecules
    Publication number: 20050025764
    Abstract: The present invention relates to CD20 binding molecules and nucleic acid sequences encoding CD20 binding molecules. In particular, the present invention relates to CD20 binding molecules with a high binding affinity, and a low dissociation rate, with regard to human CD20. Preferably, the CD20 binding molecules of the present invention comprise light and/or heavy chain variable regions with fully human frameworks (e.g. human germline frameworks).
    Type: Application
    Filed: May 20, 2004
    Publication date: February 3, 2005
    Inventors: Jeffry Watkins, Julian Davies, David Marquis, Barrett Allan, Brian Ondek
  • Fc region variants
    Publication number: 20040002587
    Abstract: The present invention provides polypeptide Fe region variants and oligonucleotides encoding Fc region variants. Specifically, the present invention provides compositions comprising novel Fc region variants, methods for identifying useful Fc region variants, and methods for employing Fc region variants for treating disease.
    Type: Application
    Filed: February 20, 2003
    Publication date: January 1, 2004
    Inventors: Jeffry D. Watkins, Barrett Allan